recommendations that such routine therapy should be halted because of the risk of inducing fatal bone marrow aplasia.s It has been universally recognised that bone marrow toxicity can follow systemic administration of chloramphenicol.9-12 This adverse reaction has taken one of two forms.13 The first was the rare, irreversible, idiosyncratic aplastic anaemia that occurred in predisposed patients independent of dose. This was thought to be mediated by a nitroreduction derivative of chloramphenicol which induced DNA damage in replicating haematopoietic stem cells, resulting in marrow hypocellularity and progressive pancytopenia. The second was the more common reaction of a generally reversible marrow suppression, which occurred in a dose dependent manner with sustained serum levels greater than 25 mg/l. This has been associated with the inhibition of mitochondrial protein synthesis and characterised by mild marrow hypocellularity with a mild anaemia, thrombocytopenia and neutropenia. In a recent review of the pathophysiology of acquired aplastic anaemia, the authors argued that bone marrow failure resulted from immunologically mediated, tissue-specific organ destruction.14 Whether chloramphenicol acted as an antigenic stimulus was not discussed.
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A critical review of both the published literature and Committee on Safety of Medicines case reports was undertaken, these forming the circumstantial evidence for the existence of an idiosyncratic haematopoietic reaction following topical chloramphenicol. The existence of this disorder would be assessed by examination of Scottish epidemiological data. Current levels of topical chloramphenicol prescription were set against the actual incidence of aplastic anaemia, and compared with that expected from known risk rates associated with chloramphenicol use.
It has been suggested that systemic effects may be achieved following topical chloramphenicol administration.8 Standard treatment with chloramphenicol 0.5% eye drops applied 4 times daily approximates to a dose of the nasolacrimal duct. Expected serum concentrations of chloramphenicol after topical therapy should be low, but remain to be determined. This study used high Blood was drawn into an additive-free tube, centrifuged and the serum stored at -20 0c. Serum assay for analyte was carried out by high-performance liquid chromatography (minimum detection limit 1 mg/l) using an RP-CI8 column with a methanol and water eluant, and absorption at 280 nm.
An estimate of patient compliance was made by subtracting the weights of returned chloramphenicol bottles from the mean weight of a full bottle (n = 10) to obtain the weight of drops used. The doses of chloramphenicol assumed to be instilled into the conjunctival sac were calculated.
Results
Seven published case reports in the world literature of topical chloramphenicol being associated with aplastic anaemia were identified for review l5-21 (Table 1) . Three of these patients were given other marrow toxic medication concurrently (C, D, G); 2 patients had liver disease (C, G); 3 patients received prolonged treatment (A, C, E); and the possibility of genetic predisposition was noted in 3 patients (A, D, G).
In the UK between 1966 and 1997 there were 11
reports to the Committee on Safety of Medicines detailing suspected ophthalmic chloramphenicol-related haematopoietic reactions which were reviewed ( Table 2) . The duration of treatment was not recorded in 5 patients (I, 2, 3, 5, 6), and was excessive in 2 patients (7, 8) . Two patients had additional treatments that were possible causes of bone marrow suppression (8, 11) . In Scotland, during the financial year April to March 1995/6, there were 128 284 prescriptions for guttae 0.5% chloramphenicol (10 ml bottles) completed by general practitioners (personal communication, The Scottish Office), with a further 42 852 supplied by 45 Scottish hospitals (personal communications to hospital pharmacies, n = 73). Allowing for the 28 non-responding hospitals, a total of approximately 198 500 guttae chloramphenicol treatment episodes was estimated. Although the rate of repeat prescriptions was unknown, these figures would be consistent with 3-4% (1 in 25) of the Scottish population being exposed to chloramphenicol eye drops. Information regarding the prescription of chloramphenicol ointment was not directly sought; where it was detailed, however, it exceeded drop therapy usage for that particular hospital.
The total annual number of prescriptions for topical chloramphenicol may therefore approach 400 000 (1 in 12 population exposure). The doses of chloramphenicol used by 15 group I patients ranged from 2.9 mg to lS.l mg, and the doses used by group II patients ranged from 3.6 mg to 32.1 mg (Table 3) . Chloramphenicol eye drops were used by these 26 patients, and as such compliance proved satisfactory. Six of 15 patients in group I, and 4 of 11 patients in group II used less than the recommended daily dose of 1 mg, suggesting some missed applications. Compliance could not be assessed in 14 patients who failed to return their chloramphenicol bottles. The results from these questionably compliant patients were included as this reflected a typical clinical situation. In their editorial, Doona and Walsh8 reiterated the fears that topical chloramphenicol may precipitate fatal aplastic anaemia and called for its routine use to be discontinued. To support their case, they cited 'numerous' articles directly implicating chloramphenicol eye drops as having caused bone marrow aplasia. Their argument was based on the understanding that chloramphenicol-related, idiosyncratic aplastic anaemia occurred independent of dose, and on the assumption that topical administration of chloramphenicol 'achieves systemic effects'. They postulated that the risk may therefore be similar to that after oral therapy.
As we have seen, of the 7 case reports reviewed from the world literature, 3 patients received other marrow toxic medication that may have been responsible for the development of aplastic anaemia. Direct causality has not been irrefutably proven in the remaining 4 cases, as coincidences may occur?4
Idiopathic aplastic anaemia has a global incidence of 3 per 1 000 000 population,25 a rate recently confirmed in Scotland.26 Aplastic anaemia developing after systemic chloramphenicol therapy has an associated risk estimated at 1 in 24 500 to 1 in 40 800 exposures?? Over the last three decades, topical chloramphenicol has been used extensively worldwide, without generating cases of associated bone marrow toxicity in numbers consistent with Doona and Walsh's postulate that the risk approaches that associated with systemic exposure?, [28] [29] [30] [31] [32] In Scotland, with a population of 5.1 million, around 15 new cases of idiopathic aplastic anaemia are expected annually. If topical chloramphenicol were responsible for cases of aplastic anaemia consistent with the risk figures quoted above, each year Scotland would expect 4 to 8 afflicted patients after drop therapy, with perhaps 8 to 16 cases if ointment therapy was included. On this basis, virtually all of the 15 so-called 'idiopathic' cases of aplastic anaemia would be directly attributable to topical chloramphenicol. This has not been observed in practice. The possibility of serious under-reporting of such frequently expected episodes would be unlikely.
The lack of an association between topical chloramphenicol and haematopoietic disorders was supported epidemiologically elsewhere. In a southern region of The Netherlands, with a population of 265 000, a 4 year study revealed that a total of 34 240 patients had used topical chloramphenicol. Of the 59 cases of idiopathic blood dyscrasias identified during this time, none could be unequivocally linked with previous topical chloramphenicol exposure ? We await with interest the results of the UK aplastic anaemia prospective epidemiological study, anticipating further clarification of this issue?8
Conclusions
Epidemiological data do not support the occurrence of idiosyncratic blood dyscrasias after topical chloramphenicol. Case reports are extremely rare; some are refutable, others may be coincidental. An adverse reaction cannot be excluded, however, in patients with a genetic predisposition, after prolonged treatment periods, or when treatment is combined with other myelotoxic drugs.
The results of our study show that, after topical application of chloramphenicol for up to 2 weeks, serum concentrations do not accumulate to detectable levels (1 mg/l). Topical chloramphenicol therefore does not present a risk of inducing dose-related bone marrow toxicity. Current evidence supports continued short-course use of topical chloramphenicol, but a personal or family history of blood dyscrasias must be excluded before prescribing.
